Retrophin to Present at Upcoming Investor Conferences
Retrophin (NASDAQ: RTRX) is participating in two virtual investor conferences in August 2020.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Retrophin (NASDAQ: RTRX) is participating in two virtual investor conferences in August 2020. The William Blair Biotech Focus Conference will occur on August 6 at 3:00 p.m. ET, followed by the Canaccord Genuity 40th Annual Growth Conference on August 12 at 2:00 p.m. ET. Live webcasts and archived replays will be available for up to 30 days on their website.
Retrophin specializes in therapies for rare diseases, focusing on late-stage development of sparsentan for conditions like FSGS and IgAN, with ongoing research in other rare disorders.
Details
News Market Reaction – RTRX
The recorded move for RTRX in the trading session of this news was -3.87%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Company management will participate in the following upcoming virtual investor conferences in August:
William Blair Biotech Focus Conference 2020
Date: Thursday, August 6, 2020
Time: 3:00 p.m. ET
Canaccord Genuity 40th Annual Growth Conference
Date: Wednesday, August 12, 2020
Time: 2:00 p.m. ET
Live webcasts will be available at http://ir.retrophin.com/events and archived replays will be accessible for up to 30 days.
About Retrophin
Retrophin is a biopharmaceutical company specializing in identifying, developing and delivering life-changing therapies to people living with rare disease. The Company’s approach centers on its pipeline featuring sparsentan, a product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN), rare disorders characterized by progressive scarring of the kidney often leading to end-stage renal disease. Research in additional rare diseases is also underway, including partnerships with leaders in patient advocacy and government research to identify potential therapeutics for NGLY1 deficiency and Alagille syndrome, conditions with no approved treatment options. Retrophin’s R&D efforts are supported by revenues from the Company’s commercial products Chenodal®, Cholbam®, Thiola® and Thiola EC®.
Contact:
Chris Cline, CFA
Senior Vice President, Investor Relations & Corporate Communications
888-969-7879
IR@retrophin.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.